Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Personnel Costs Drop: Is The Next Generation Taking Over?

A businessman in blue shirt is holding a magnifying glass in his hand, is searching for personnel or people. Detective looking for missing person crowd of miniature figures choosing most suitable one - Image — Personnel costs for human and generic drug review increased, while personnel costs for biosimilar review decreased, in FY 2019 compared to the previous year. • Source: Shutterstock

Related Content

US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities

Feb 11 2020

US FDA's Biologics Center May Get Its Day In PDUFA VII

Jul 23 2020

Generic Drug User Fee Program Sees First-Ever Fee Spending Decrease, FTE Decline

Jul 13 2020

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

Jun 23 2020

PDUFA Needs More Than 300 Additional FTEs, New US FDA Capacity Planning Formula Says

Aug 06 2020

Cures Act Hiring Authority Expansion Could Help Recruitment Woes, US FDA's Sharpless Says

Jun 20 2019

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

May 01 2019

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

Generic Drug Review Costs Still Largely Non-Personnel Related

Aug 10 2015

US FDA Hiring Strategy Shifts Focus From ‘Vacancies’ To ‘Net Gains’

Sep 04 2020

Gottlieb: The Next Janet Woodcock Is Waiting To Be Discovered At FDA

Nov 09 2017

Additional Topics

United States FDA User Fees Leadership Regulation Biosimilars Drug Review Generic Drugs Review Pathway BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window